NCT01979523View on ClinicalTrials.gov

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 21, 2013

Primary Completion Date

September 1, 2017

Study Completion Date

July 2, 2026

Conditions
Recurrent Uveal MelanomaStage IV Uveal Melanoma AJCC v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Trametinib

Given PO

DRUG

Uprosertib

Given PO

Trial Locations (7)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

37232

Vanderbilt University/Ingram Cancer Center, Nashville

75005

Institut Curie Paris, Paris

77030

M D Anderson Cancer Center, Houston

L69 3GA

The University of Liverpool, Liverpool

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH